Skip to main content

A biologic you know, now approved in chronic spontaneous urticaria (CSU)

Efficacy demonstrated at week 24 in CUPID-A and CUPID-C studies
Demonstrated safety profile
Dupixent offers the option of at-home administration
Patient support

Trial design In
biologic-naivea patients

HSS7, hives severity score over 7 days; ISS7, itch severity score over 7 days; Q2W, once every 2 weeks; UAS7, urticaria activity score over 7 days.

  • aBiologic defined as anti-IgE treatment (omalizumab) 4 months prior to screening.
Adverse reactions occurring in ≥2% of patients through Week 241
POOLED ACROSS CUPID STUDIES A, B, AND Ca
Adverse
reaction
DUPIXENT
200/300 mg Q2W
(n=195)
%
Placebo
(n=197)
%
Injection site
reactionb
10 8

Rate of treatment discontinuation
at Week 241,a

Rate of discontinuations due to
adverse events vs placebo
1.0% DUPIXENT
vs
2.5% PLACEBO
  • Patients should discontinue DUPIXENT if a clinically significant hypersensitivity reaction occurs or until a parasitic (helminth) infection resolves in a patient who does not respond to anti-helminth treatment1

Safety profile studied
in >8900 patients
across us-approved
indications1,c

  • aPooled safety population from CUPID studies A, B, and C. CUPID-B was an identically designed study that enrolled 108 CSU patients (aged 12 years or older) who were inadequate responders (N=104) to H1 antihistamines and anti-IgE treatments or intolerant (N=4) to anti-IgE therapy. The efficacy of DUPIXENT was based only on CUPID Study A and Study C; Study B did not meet the primary endpoint.
  • bInjection site reactions cluster includes injection site dermatitis, injection site erythema, injection site hematoma, injection site induration, injection site pain, injection site pruritus, injection site reaction, injection site swelling.
  • cPatient total included patients in AD trials (SOLO 1, SOLO 2, CHRONOS, AD-1021, AD-1526, AD-1652, AD-1539, and AD-HAFT), asthma trials (DRI12544, QUEST, VENTURE, and VOYAGE), CRSwNP trials (SINUS-24 and SINUS-52), EoE trials (EoE-1 and EoE-2), PN trials (PRIME and PRIME2), COPD trials (BOREAS and NOTUS), and CSU trials (CUPID-A, CUPID-B, and CUPID-C).
  • AD, atopic dermatitis; COPD, chronic obstructive pulmonary disease; CRSwNP, chronic rhinosinusitis with nasal polyps; EoE, eosinophilic esophagitis; PN,
    prurigo nodularis; Q2W, once every 2 weeks.

DUPIXENT Attributes And Considerations

NOT AN
IMMUNOSUPPRESSANT
OR A STEROID1

NO INITIAL LAB
TESTING OR
ONGOING
LAB MONITORING

according to the
Prescribing Information1

NO KNOWN DRUG‑TO‑DRUG INTERACTIONS1

  • Not metabolized through
    the liver or
    excreted
    through the kidneys

At-home
self-administration1

  • Train patients and/or
    caregivers on
    proper
    administration prior to use

NO boxed warning1

Please see additional
Warnings and Precautions
in the Prescribing
Information and Important
Safety Information below.

Select important safety information

WARNINGS AND PRECAUTIONS

Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions, angioedema, generalized
urticaria, rash, erythema nodosum, and erythema multiforme have been reported. If a clinically significant hypersensitivity reaction occurs,
institute appropriate therapy and discontinue DUPIXENT.

Please see additional Warnings and Precautions in the Prescribing Information and Important Safety Information below.

Train patients and/or caregivers on proper administration prior to use.

A dosing schedule you are familiar with, now in CSU: one dose every 2 weeks after an initial loading dose1

18+ YEARS

One dosage regimen
in adults
regardless
of weight

Initial loading dose:

600 mg 2 x 300 mg

12 TO 17 YEARS

≥60 kg

600 mg 2 x 300 mg

30 to <60 kg

400 mg 2 x 200 mg
  • a30 kg is equal to 66 lb; 60 kg is equal to 132 lb.
Dupixent® (dupilumab) 200mg or 300mg pre-filled pen and syringe for ages 12 years and up Dupixent® (dupliumab) 200mg or 300mg pre-filled pen and syringe for ages 12 years and up
 

Available in a 200 mg
or 300 mg pre-filled pen

or pre-filled syringe
for subcutaneous
injection1

Dupixent® (dupliumab) 200mg or 300mg pre-filled pen and syringe for ages 12 years and up
Consider before injecting
DUPIXENT is administered by subcutaneous injection and is intended for use under the guidance
of a healthcare provider1
DUPIXENT is administered by subcutaneous injection and is intended for use under the guidance
of a healthcare provider1
  • Provide proper training to patients and/or caregivers on the preparation and administration of DUPIXENT prior to use, according to the Instructions for Use1
  • Rotate injection site with each injection1
  • A caregiver or patient 12 years of age and older may inject DUPIXENT after training in subcutaneous injection technique using the pre-filled syringe or pre-filled pen. In children 12 years of age and older, it is recommended that DUPIXENT be given by or under the supervision of an adult1
  • Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating treatment with DUPIXENT1
DUPIXENT MyWay® Logo

DUPIXENT MyWay is a patient support program that can help enable access to DUPIXENT and offers financial assistance for eligible patients, one-on-one nursing support, and more.

DUPIXENT MyWay
ENROLLMENT FORM

English Enrollment Form
Spanish Enrollment Form

Now approved for patients 12+ years of age
with csu who remain symptomatic despite
h1 antihistamines

Connect with a DUPIXENT Field Representative to get
answers to your product-related questions.

contact a rep